Sight Sciences has announced a positive trial verdict in a $34m patent infringement case against Alcon and its minimally invasive glaucoma surgery (MIGS) device, the Hydrus Microstent.

The jury on the case, which Sight Sciences filed in 2021 in the District Court for the District of Delaware, found that Alcon subsidiaries, including Ivantis, which it acquired in 2021, willfully infringed on three of Sight Sciences’ asserted patents.

The case concerns US Patents Nos. 8,287,482, 9,370,443 and 11,389,328, which describe and claim devices and methods for reducing intraocular pressure in the eye.

Monetary damages in the ruling are comprised of $5.5m in lost profits and $28.5m in royalty damages for sales of the Ivantus-manufactured Hydrus Microstent for the period of its commercial launch through trial.

Sight Sciences co-founder and CEO Paul Badawi said: “Over the past 18 years, we have pioneered various important and proprietary micro-invasive surgical glaucoma methods and devices, including intra-canalicular scaffolding, bladeless goniotomy, ab interno canaloplasty, ab interno trabeculotomy, and combinations of these methods.

“Given the substantial investments we have made in our surgical innovations on behalf of our surgeon customers and glaucoma patients, we believe safeguarding our intellectual property portfolio is paramount, and we are pleased with the jury’s verdict.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Food and Drug Administration granted 510(k) clearance for Sight Sciences’ TearCare System and its OMNI surgical system to reduce intraocular pressure in patients with primary open-angle glaucoma in 2021 and 2024 respectively.

GlobalData’s Databook found that Sight Sciences saw the highest growth of 19% in patent filings in October and 99% in grants in November in Q4 2023. Meanwhile, the company’s Market Model methodology determined that Alcon, which spun off from former parent company Novartis in 2019 to become an independent entity, was the leading player in the glaucoma surgery devices market in the US in 2022.